12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afirma: Pivotal trial data

An ongoing U.S. pivotal trial evaluating 66 thyroid nodule FNA samples for which surgical pathology results were known showed that Veracyte's Afirma molecular classifier had 97% sensitivity, 64% specificity and a NPV of 98% for identifying benign tumors when compared to the current standard of 2 blinded expert histopathology reviews. In...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >